OncoMatch/Clinical Trials/NCT07025226
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
Is NCT07025226 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments for glioma.
Treatment: Dasatinib · Fisetin · Fluorodopa F 18 · Quercetin · Temozolomide — This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin and temozolomide work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the tumor have been made (residual disease). Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals tumor cells to multiply, which may help keep tumor cells from growing. Quercetin and fisetin are compounds found in plants. They have antioxidant and anti-inflammatory properties and help remove senescent cells, older or damaged cells that have stopped dividing but don't die off as they should and build up in tissues over time. Senescent cells may cause inflammation or damage to nearby healthy cells. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. Giving medication combinations of dasatinib, quercetin, fisetin and temozolomide may be safe, tolerable and/or effective in treating patients with previously treated glioma with residual disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
Must have IDH-mutant OR MGMT-methylated glioma
Required: MGMT methylation
Must have IDH-mutant OR MGMT-methylated glioma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
treated with chemotherapy and/or radiation
Must have received: radiation therapy
treated with chemotherapy and/or radiation
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL; ANC ≥ 1500/mm^3; Platelet count ≥ 100,000/mm^3 (without transfusion ≤ 7 days preceding lab assessment) (≤ 15 days prior to registration)
Kidney function
Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula (≤ 15 days prior to registration)
Liver function
ALT and AST ≤ 2.5 x ULN (or ≤ 5 x ULN for patients with liver involvement) (≤ 15 days prior to registration)
Cardiac function
Average corrected QT interval (QTc) ≤ 450 ms on triplicate 12 lead ECG ≤ 29 days prior to registration (Fridericia's formula)
Hemoglobin ≥ 9.0 g/dL (≤ 15 days prior to registration); ANC ≥ 1500/mm^3 (≤ 15 days prior to registration); Platelet count ≥ 100,000/mm^3 (without transfusion ≤ 7 days preceding lab assessment) (≤ 15 days prior to registration); ALT and AST ≤ 2.5 x ULN (or ≤ 5 x ULN for patients with liver involvement) (≤ 15 days prior to registration); Calculated creatinine clearance ≥ 45 ml/min using the Cockcroft-Gault formula (≤ 15 days prior to registration); Average corrected QT interval (QTc) ≤ 450 ms on triplicate 12 lead electrocardiogram (ECG) ≤ 29 days prior to registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Rochester · Rochester, Minnesota
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify